Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% in the fourth quarter, Holdings Channel reports. The firm owned 22,886,162 shares of the medical equipment provider’s stock after selling 398,676 shares during the quarter. Vanguard Group Inc. owned 0.11% of Zimmer Biomet worth $2,417,465,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Intech Investment Management LLC increased its position in Zimmer Biomet by 21.3% in the 3rd quarter. Intech Investment Management LLC now owns 2,379 shares of the medical equipment provider’s stock valued at $257,000 after acquiring an additional 417 shares during the period. Cerity Partners LLC grew its stake in shares of Zimmer Biomet by 28.7% in the 3rd quarter. Cerity Partners LLC now owns 40,307 shares of the medical equipment provider’s stock valued at $4,351,000 after purchasing an additional 8,999 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Zimmer Biomet by 61.9% in the third quarter. Larson Financial Group LLC now owns 3,407 shares of the medical equipment provider’s stock valued at $368,000 after purchasing an additional 1,302 shares during the period. Daiwa Securities Group Inc. raised its stake in shares of Zimmer Biomet by 6.9% during the third quarter. Daiwa Securities Group Inc. now owns 25,133 shares of the medical equipment provider’s stock worth $2,713,000 after purchasing an additional 1,618 shares during the last quarter. Finally, Brown Brothers Harriman & Co. lifted its holdings in shares of Zimmer Biomet by 12.1% during the third quarter. Brown Brothers Harriman & Co. now owns 1,806 shares of the medical equipment provider’s stock worth $195,000 after purchasing an additional 195 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on ZBH shares. Truist Financial restated a “hold” rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Finally, Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Trading Down 0.7 %

Shares of Zimmer Biomet stock opened at $110.50 on Wednesday. The business has a 50 day moving average price of $106.98 and a 200 day moving average price of $106.90. The company has a market capitalization of $22.00 billion, a P/E ratio of 24.83, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business earned $2.20 earnings per share. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.